SupelMIP SPE phases were developed by MIP Technologies AB, which is one of the leading authorities and commercial pioneers of molecular imprinted polymers for process scale separations, analytical chromatography, and sample preparation.
The SupelMIP SPE line consist s of highly cross-linked polymers that are engineered to extract a single analyte of interest or a class of structurally related analytes with an extremely high degree of selectivity. This is possible because selectivity is introduced during MIP synthesis in which a template molecule, designed to mimic the analyte, guides the formation of specific cavities or imprints that are sterically and chemically complementary to the analyte(s) of interest.
By careful design of the imprinting site, either by molecular modeling, experimental design, or screening methods, the binding cavities can be engineered to offer multiple interaction points with the analyte(s) of interest. This leads to a stronger interaction between the solid-phase and the analyte(s). As a consequence, harsher wash conditions can be tolerated during SPE methodology resulting in cleaner extracts. Because extraction selectivity is significantly improved, lower background is observed allowing analysts to achieve lower limits of detection.
A highly selective MIP phase for the selective extraction of tobacco-specific nitrosamine NNAL in biological fluids.
Unlike conventional extraction methods which are elaborate and time-consuming, SupelMIP SPE - NNAL offers a simple and efficient extraction method for quantitating NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). The method offers consistent and excellent selectivity and recoveries for both free and total NNAL with and without the presence of nicotine. Detailed extraction protocols are included with the product.
Features and Benefits
Highly selective SPE for trace analysis in complex matrices
Achieve lower detection limits
Significant time and cost savings
SupelMIP is a registered trademark of Sigma-Aldrich Co. LLC
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.